Lundbeck partner soon to seek approval for new Abilify Maintena version

Japanese Otsuka, Lundbeck's partner in sharing rights for Abilify Maintena, signals plans to seek marketing approval for a longer-acting version of the drug – a move that could extend the medication's patent protection.

Photo: Thomas Borberg

The term of Abilify Maintena's patent protection could be substantially extended. Japanese Otsuka, Lundbeck's partner for the drug, is in the process of preparing to seek approval for a new and longer-acting version of the medication.

Lundbeck informs in its most recent interim report that Otsuka has entered the final stages leading up the application. The latter is said to be finalizing its new production setup, which requires validation before an approval can be issued, and Lundbeck Chief Executive Deborah Dunsire says the partner is far along in the process.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs